Repros Therapeutics, Inc. (RPRX) Posts Q1 EPS Loss of $0.20
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Join SI Premium – FREE
Repros Therapeutics, Inc. (NASDAQ: RPRX) reported Q1 EPS of ($0.20), $0.03 worse than the analyst estimate of ($0.17).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
- Reading (RDI) Tops Q2 EPS by 4c
- Zealand Pharma sells rusfertide royalty rights to Royalty Pharma for $100M
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
